Efficacy and safety of asciminib, a specific allosteric BCR-ABL1 inhibitor targeting the myristoyl-binding site, in patients with chronic myeloid leukemia (CML) carrying the T315I mutation Meeting Abstract
| Authors: | Deininger, M. W.; Réa, D.; Lang, F.; Kim, D. W.; Cortes, J. E.; Hughes, T. P.; Minami, H.; Breccia, M.; DeAngelo, D. J.; Hochhaus, A.; Talpaz, M.; Goh, Y. T.; Le Coutre, P. D.; Etienne, G.; Sondhi, M.; Mishra, K.; Aimone, P.; Mauro, M. J. |
| Abstract Title: | Efficacy and safety of asciminib, a specific allosteric BCR-ABL1 inhibitor targeting the myristoyl-binding site, in patients with chronic myeloid leukemia (CML) carrying the T315I mutation |
| Meeting Title: | 7th Annual Meeting of the Society of Hematologic Oncology (SOHO 2019) |
| Keywords: | clinical trial; cml; tyrosine kinase inhibitor; chronic; myelogenous leukemia; asciminib |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 19 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2019 Sep 11-14 |
| Meeting Location: | Houston, TX |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2019-09-01 |
| Start Page: | S289 |
| End Page: | S290 |
| Language: | English |
| ACCESSION: | WOS:000483480700271 |
| DOI: | 10.1016/j.clml.2019.07.234 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: CML-045 -- Source: Wos |
